➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Merck
Colorcon
Moodys
McKinsey
Medtronic

Last Updated: March 6, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PLENVU

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for PLENVU

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03437265 A Pharmacokinetic Study of NER1006 in Healthy Subjects Not yet recruiting Quotient Clinical Phase 1 2018-04-04 This study characterises the pharmacokinetic (PK) profile of the active ingredients of NER1006 and their related substances/metabolites. Subjects will receive NER1006.
NCT03437265 A Pharmacokinetic Study of NER1006 in Healthy Subjects Not yet recruiting Norgine Phase 1 2018-04-04 This study characterises the pharmacokinetic (PK) profile of the active ingredients of NER1006 and their related substances/metabolites. Subjects will receive NER1006.
NCT03742232 Study Comparing the Bowel Cleansing Efficacy of PLENVU® Versus SELG-ESSE® Using a 2-Day Split Dosing Regimen. Active, not recruiting Istituto Clinico Humanitas Phase 4 2018-10-31 This study is a multicentre randomized parallel group phase IV study comparing the bowel cleansing efficacy, safety and tolerability of PLENVU® (a 1 litre PEG Bowel Cleansing Solution) versus SELG-ESSE® (a 4 litre PEG Bowel Cleansing Solution) using a 2-Day Split Dosing Regimen.
NCT04297423 Two Low Volume Regimens for Colorectal Cancer Screening Colonoscopy Not yet recruiting Casen Recordati S.L. Phase 4 2020-03-17 Colorectal cancer is the first neoplasm most commonly diagnosed in both sexes and the second leading cause of cancer death in Spain. Colorectal cancer screening Program in Barcelona was implanted in 2009 and approximately 1,500 colorectal cancer screening colonoscopies are performed annually at Hospital Clínic de Barcelona. Adequate colon preparation (anterograde cleansing with laxatives) improves polyp detection, decreases examination time, and complications. There are both low and high volume intestinal regimens with polyethylene glycol (PEG) as the main active ingredient or without it. Hypothesis: Two low volumen regimens, 1L PEG plus ascorbate and magnesium citrate plus picosulphate, at starting doses have the same Adenoma Detection Rate as cleansing solutions in preparation for screening colonoscopy.
NCT04297423 Two Low Volume Regimens for Colorectal Cancer Screening Colonoscopy Not yet recruiting Fundacion Clinic per a la Recerca Biomédica Phase 4 2020-03-17 Colorectal cancer is the first neoplasm most commonly diagnosed in both sexes and the second leading cause of cancer death in Spain. Colorectal cancer screening Program in Barcelona was implanted in 2009 and approximately 1,500 colorectal cancer screening colonoscopies are performed annually at Hospital Clínic de Barcelona. Adequate colon preparation (anterograde cleansing with laxatives) improves polyp detection, decreases examination time, and complications. There are both low and high volume intestinal regimens with polyethylene glycol (PEG) as the main active ingredient or without it. Hypothesis: Two low volumen regimens, 1L PEG plus ascorbate and magnesium citrate plus picosulphate, at starting doses have the same Adenoma Detection Rate as cleansing solutions in preparation for screening colonoscopy.
NCT04297423 Two Low Volume Regimens for Colorectal Cancer Screening Colonoscopy Not yet recruiting Hospital Clinic of Barcelona Phase 4 2020-03-17 Colorectal cancer is the first neoplasm most commonly diagnosed in both sexes and the second leading cause of cancer death in Spain. Colorectal cancer screening Program in Barcelona was implanted in 2009 and approximately 1,500 colorectal cancer screening colonoscopies are performed annually at Hospital Clínic de Barcelona. Adequate colon preparation (anterograde cleansing with laxatives) improves polyp detection, decreases examination time, and complications. There are both low and high volume intestinal regimens with polyethylene glycol (PEG) as the main active ingredient or without it. Hypothesis: Two low volumen regimens, 1L PEG plus ascorbate and magnesium citrate plus picosulphate, at starting doses have the same Adenoma Detection Rate as cleansing solutions in preparation for screening colonoscopy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for PLENVU

Condition Name

Condition Name for PLENVU
Intervention Trials
Colon Lesion 1
Colon Adenoma 1
Pharmacokinetic 1
Colorectal Cancer 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for PLENVU
Intervention Trials
Colorectal Neoplasms 1
Adenoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for PLENVU

Trials by Country

Trials by Country for PLENVU
Location Trials
Italy 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for PLENVU

Clinical Trial Phase

Clinical Trial Phase for PLENVU
Clinical Trial Phase Trials
Phase 4 2
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for PLENVU
Clinical Trial Phase Trials
Not yet recruiting 2
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for PLENVU

Sponsor Name

Sponsor Name for PLENVU
Sponsor Trials
Casen Recordati S.L. 1
Istituto Clinico Humanitas 1
Norgine 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for PLENVU
Sponsor Trials
Other 4
Industry 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
McKesson
Colorcon
Express Scripts
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.